Immix Biopharma - US CAR-T trial commences patient dosing
Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead...
194 Views
Immix Biopharma - All roads lead to NEXICART-2
Immix Biopharma’s Q124 report reflected a period focused on its lead CAR-T asset, NXC-201, targeting amyloid light chain amyloidosis (ALA), which...
205 Views
Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T
Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with...
287 Views
Immix Biopharma - Marching towards US clinical trials for NXC-201
Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer...
261 Views
Immix Biopharma - 2023 recap with a preview of active year ahead
IMMX has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T...
192 Views